A Fixed Combination of Palmitoylethanolamide and Melatonin (PEATONIDE) for the Management of Pain, Sleep, and Disability in Patients with Fibromyalgia: A Pilot Study
Open-label, no control groupHumansWith melatonin
This study tested palmitoylethanolamide together with melatonin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 50 patients with fibromyalgia. All completed.
- Dose used in the study
- 1,200 mg of palmitoylethanolamide with 0.2 mg of melatonin, once a day at bedtime
- Duration
- 3 months, then 1 month off treatment
- What was measured
- Pain on a visual analogue scale, an insomnia severity index, a disability questionnaire and tender point count.
What the authors reported
At 1 month pain fell by 1.16 points and the insomnia score improved by 6.24 points (both p < 0.01). Improvements held at 3 months and were partly kept after treatment stopped. No adverse events were reported.
Limits of this study
There was no control group, which the authors name as a limit. Melatonin is itself used for sleep, so the sleep result cannot be assigned to palmitoylethanolamide. The authors declared no conflicts. The funding statement was not visible on the page checked.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.